PH12014502314B1 - Optimised subcutaneous therapeutic agents - Google Patents

Optimised subcutaneous therapeutic agents

Info

Publication number
PH12014502314B1
PH12014502314B1 PH12014502314A PH12014502314A PH12014502314B1 PH 12014502314 B1 PH12014502314 B1 PH 12014502314B1 PH 12014502314 A PH12014502314 A PH 12014502314A PH 12014502314 A PH12014502314 A PH 12014502314A PH 12014502314 B1 PH12014502314 B1 PH 12014502314B1
Authority
PH
Philippines
Prior art keywords
therapeutic agents
optimised
subcutaneous therapeutic
cmax
subcutaneous
Prior art date
Application number
PH12014502314A
Other languages
English (en)
Other versions
PH12014502314A1 (en
Inventor
William Henry
Richard Wolf-Garraway
John Charles Mayo
Michael James Earl
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of PH12014502314A1 publication Critical patent/PH12014502314A1/en
Publication of PH12014502314B1 publication Critical patent/PH12014502314B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12014502314A 2012-04-16 2014-10-15 Optimised subcutaneous therapeutic agents PH12014502314B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Publications (2)

Publication Number Publication Date
PH12014502314A1 PH12014502314A1 (en) 2015-01-12
PH12014502314B1 true PH12014502314B1 (en) 2020-01-31

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502314A PH12014502314B1 (en) 2012-04-16 2014-10-15 Optimised subcutaneous therapeutic agents

Country Status (29)

Country Link
US (2) US20150086524A1 (forum.php)
EP (1) EP2838566A2 (forum.php)
JP (3) JP2015512927A (forum.php)
KR (1) KR102137290B1 (forum.php)
CN (1) CN104411335A (forum.php)
AP (1) AP2014008049A0 (forum.php)
AU (3) AU2013248296A1 (forum.php)
BR (1) BR112014025737A2 (forum.php)
CA (1) CA2869993C (forum.php)
CL (1) CL2014002773A1 (forum.php)
CO (1) CO7151496A2 (forum.php)
CR (1) CR20140475A (forum.php)
EA (1) EA033469B1 (forum.php)
EC (1) ECSP14023048A (forum.php)
GB (3) GB201910184D0 (forum.php)
GE (1) GEP201706716B (forum.php)
HK (1) HK1200695A1 (forum.php)
IL (1) IL235129B (forum.php)
IN (1) IN2014DN08598A (forum.php)
MD (1) MD20140123A2 (forum.php)
MX (2) MX2014012512A (forum.php)
MY (1) MY190257A (forum.php)
NI (1) NI201400122A (forum.php)
NZ (1) NZ701205A (forum.php)
PE (1) PE20150226A1 (forum.php)
PH (1) PH12014502314B1 (forum.php)
SG (1) SG11201406492YA (forum.php)
WO (1) WO2013156488A2 (forum.php)
ZA (1) ZA201407370B (forum.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2016198641A1 (en) * 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
WO2021216372A1 (en) * 2020-04-23 2021-10-28 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (forum.php) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
CA2145407C (en) 1992-09-28 2009-09-22 Louis A. Carpino New reagents for peptide couplings
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JPH08325270A (ja) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co β−ラクタマーゼに対するポリマープロドラッグおよびその使用
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2003240439B2 (en) * 2002-06-21 2009-05-21 Novo Nordisk Health Care Ag Pegylated factor VII glycoforms
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
MXPA05009169A (es) * 2003-02-26 2005-11-17 Nektar Therapeutics Al Corp Conjugados de polimero-porcion del factor viii.
PT1620118E (pt) * 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
DE602005014447D1 (de) 2004-03-04 2009-06-25 Eisai R&D Man Co Ltd Zusammensetzung mit benzamidin-derivat und verfahren zur stabilisierung von benzamidin-derivat
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
EP2059527B1 (en) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
JP5558106B2 (ja) 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
KR20100090684A (ko) 2007-10-09 2010-08-16 폴리테릭스 리미티드 신규한 접합 단백질 및 펩티드
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2721362A1 (en) * 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
MX2010011672A (es) * 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
US20110112029A1 (en) * 2008-05-23 2011-05-12 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
PL2349341T3 (pl) * 2008-10-15 2014-03-31 Baxalta Inc Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych
HUE039906T2 (hu) * 2008-10-17 2019-02-28 Baxalta GmbH Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
AU2010281453C1 (en) * 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
SG187171A1 (en) * 2010-07-30 2013-02-28 Baxter Int Nucleophilic catalysts for oxime linkage
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
CR20140475A (es) 2015-01-23
JP2015512927A (ja) 2015-04-30
IN2014DN08598A (forum.php) 2015-05-22
KR102137290B1 (ko) 2020-07-23
GB201910184D0 (en) 2019-08-28
EA033469B1 (ru) 2019-10-31
JP6550107B2 (ja) 2019-07-24
EA201491702A1 (ru) 2015-03-31
GB201418864D0 (en) 2014-12-03
BR112014025737A2 (pt) 2017-07-04
CA2869993C (en) 2023-05-23
ECSP14023048A (es) 2015-11-30
PE20150226A1 (es) 2015-02-14
GB201910190D0 (en) 2019-08-28
AP2014008049A0 (en) 2014-11-30
NZ701205A (en) 2016-02-26
GEP201706716B (en) 2017-08-10
SG11201406492YA (en) 2014-11-27
MX2020014208A (es) 2021-03-09
MD20140123A2 (ro) 2015-04-30
CO7151496A2 (es) 2014-12-29
JP2018024684A (ja) 2018-02-15
MX2014012512A (es) 2015-01-15
WO2013156488A2 (en) 2013-10-24
WO2013156488A3 (en) 2014-01-16
AU2013248296A1 (en) 2014-11-13
HK1200695A1 (en) 2015-08-14
MY190257A (en) 2022-04-11
AU2020200842A1 (en) 2020-02-27
IL235129B (en) 2022-06-01
US11351112B2 (en) 2022-06-07
ZA201407370B (en) 2017-09-27
IL235129A0 (en) 2014-12-31
JP2019131593A (ja) 2019-08-08
GB2516388A (en) 2015-01-21
CL2014002773A1 (es) 2015-01-16
AU2018200111B2 (en) 2019-11-07
CN104411335A (zh) 2015-03-11
US20180036229A1 (en) 2018-02-08
PH12014502314A1 (en) 2015-01-12
NI201400122A (es) 2016-12-02
KR20140146171A (ko) 2014-12-24
CA2869993A1 (en) 2013-10-24
EP2838566A2 (en) 2015-02-25
US20150086524A1 (en) 2015-03-26
AU2018200111A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
GB201200062D0 (en) Estradiol oromucosal liquid compositions
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
MX341356B (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
PH12013502252B1 (en) Induction of il-12 using immunotherapy
WO2014093818A3 (en) Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
IN2014DN10134A (forum.php)
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2015004940A (es) Tratamiento de depresion y ptsd.
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
UA69680U (ru) Способ лечения больных фелинозом